Portfolio

GuangZhou Boxin Medical

Two-phase atherectomy for removal of atherosclerotic plaque
(2020)

Labyrinth Biotech Inc

Microfluidic technology for the isolation and capture of circulating tumor cells for research purposes and clinical diagnosis
(2020)

LynxDX, Inc

Biotechnology startup using prostate cancer diagnostic assay to measure levels of cancer specific genes in the urine. Additionally focused on scaling COVID-19 testing
(2020)

Nanjing Novall Medical Co Ltd

Nitric oxide releasing medical device technology
(2020)

Novlead Biotech

Medical devices that release nitric oxide to treat persistent pulmonary hypertension of the newborn
(2020)

NuBundle, Inc.

Suite of software and services for patients undergoing assisted reproduction treatment
(2020)

OntMed

Medical ontology and classification system used to improve search, interogation and analysis of a variety of medical data
(2020)

PTM Therapeutics

Antibody therapeutic for the treatment of inflammatory bowel disease
(2020)

Angio Insight

Automated analysis of angiograms to augment clinical decisions in managing coronary artery disease
(2019)

Arcascope

Apps developed using mathematical modeling to predict circadian rhythms to improve performance and wellness.
(2019)

Cellf BIO LLC

Cellf BIO manufactures bioengineered sphincters using autologous progenitor cells that replace the dysfunctional internal anal sphincter, the root cause of FI. This new product, called a BioSphincterTM, allows the patient to regain full control of bowel movements and rejuvenate their quality of life.
(2019)

DGD Pharmaceuticals

Mutant EGFR inhibitor for various cancer types
(2019)

GreenMark Biomedical

To enable oral healthcare professionals to preserve teeth through earlier diagnosis & non-invasive treatment.
(2019)

Immulus

Next-generation biomanufacture of cell therapies
(2019)

InheRET

Risk evaluation tool uses your personal and family health history to find out if you are at increased risk for hereditary disease using easy-to-read report with next-step recommendations helps you and your doctor make a care plan to reduce your risk
(2019)

MakeMedical

Surgeon designed, high fidelity, 3D printed surgical simulators
(2019)

MEKanistic Therapeutics

MEKanistic is innovating cancer therapies by advancing a novel class of selective kinase inhibitors rationally designed to target both EGFR and PI3K with a single molecule. This breakthrough design expands the therapeutic window while avoiding inherent toxicity challenges of multi-compound treatments. Preclinical studies of its lead drug MTX-531 show a high incidence of tumor regression with dramatically reduced toxicity. EGFR, PI3 kinase dual inhibitor (precision pharmacology)
(2019)

PP2A Therapeutics

Use of High Resolution Structure of the Tumor Suppressive PP2A-B56ɑ Holoenzyme for Drug Discovery
(2019)